Physician profile
Anna Ohearn
NPI 1396221479
$681.25
in general payments reported to CMS, 2019-2025
11 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.66 · 2023: $152 · 2024: $94.55 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $135.93 | 2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $118.94 | 2025 | |
| Abbvie INC. | $116.38 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $106.14 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Corium, LLC | $47.60 | 2023-2024 | Azstarys |
| Lundbeck LLC | $35.37 | 2022-2024 | Rexulti |
| Janssen Scientific Affairs, LLC | $32.78 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.94 | 2022 | |
| Harmony Biosciences LLC | $23.59 | 2023 | Wakix |
| Biogen, INC. | $22.96 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $17.62 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ohearn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.